Last year the AthenaDAO community chose to support Dr Mario Cordero’s work on ovarian aging. We’re excited to share the team’s promising data and announce a further fundraising round to move the project forward.

Let's face it, death is the final boss. It's the game over screen nobody wants to see. But what if you could develop your own infinite health cheat code? What if we could keep playing the game indefinitely? Let's play on pump.science.

Molecule is building a Solana-native DeSci funding platform: pump.science. Read on for more!

Molecule's platform, Catalyst, empowers individuals to directly back scientific research projects that resonate with them. We are thrilled to announce our integration with Privy, a step that amplifies accessibility and usability for our community.

An important research milestone was reached — data showed ArtanBio’s AAV9-based gene therapy for aging has activity in vitro. This milestone demonstrates the power democratized funding can have towards advancing scientific progress. Read on for more.

With the beta launch of Catalyst, Molecule invites you to embark on an exciting journey with Catalyst Quests—a gamified adventure designed to onboard users into the DeSci movement.

Early-stage biomedical research funding is plagued by a mismatch between funded and impactful research. This disconnect results in significant diseases being underfunded despite their impact on public health.

Molecule, a leader in decentralized science (DeSci) and a pioneer in tokenized intellectual property (IP), is thrilled to announce its strategic partnership with CryoDAO.

We don’t know about you, but we’re still processing all the incredible ideas and information shared at this year's DeSci.Berlin!

Sharing a mission of supporting early stage life sciences research and development, Molecule and Nucleate are joining forces to cultivate the next generation of bioentrepreneurs.

In a compelling step forward, Sora Ventures has announced a significant investment in Molecule, marking a pivotal step towards integrating Decentralized Science (DeSci) in Asia.

Moments that draw a community together act as an accelerant to progress. We recently hosted DeSci.Berlin 2023, facilitating essential conversations between key role players and encouraging knowledge to be dispensed liberally throughout the ecosystem.

Since 2018, Molecule has been at the forefront of decentralized science (DeSci). By helping to build the first biotech DAO - VitaDAO - and by creating core DeSci infrastructure like the IP-NFT framework we have laid the foundation for the next generation of builders in DeSci to emerge and reshape the life sciences. Through this process, Molecule and the DeSci community have learned a tremendous amount about building at the intersection of web3 and bio.

We are pleased to announce that Molecule’s IP-NFT funding framework will facilitate critical preclinical work in Dr. Amit Sharma’s laboratory at the SRF Research Center to eliminate the accumulation of senescent cells in age-related diseases.

Ethan Perlstein, a well-known biotech founder and rare diseases advocate recently posted on Twitter that: "once you get a taste of decentralized biotech "it’s hard to go back to the centralized carnival of yore." It's as though he was talking about decentralized science (DeSci) itself. No event gave you this feeling better than the recent DeSci.Berlin gathering.

Today, we are excited to announce that we have raised $12.7M in seed funding. Led by Northpond Ventures with participation from Shine Capital, 1kx, Fifty Years, KdT Ventures, BACKED VC, Inflection VC, Chris Leiter, Balaji Srinivasan, Zee Prime Capital, The LAO, L1 Digital, Boom Capital, Compound VC, Koji Capital, Pillar VC, Seedclub Ventures, Speedinvest, Healthspan Capital, BoxGroup and many others - we are now one step closer to creating a more equitable future for researchers and patients.

We are delighted to share that the laboratory of Evandro Fang at the Akershus University Hospital and the University of Oslo became the third ever lab to fund their research project via Molecule’s IP-NFT framework - The discovery of novel mitophagy activators for Alzheimer´s disease and healthy longevity.

A blossoming Decentralized Science (DeSci) movement is changing the biopharma landscape by enabling the formation of patient- and researcher-centric communities building with an open-source ethos.

TL;DR: This week, the first university biomedical intellectual property (IP) and research project was funded as an NFT (non-fungible token), enabled by a pioneering innovation at Molecule. The IP-NFT enables new fundraising and collaboration strategies for researchers by combining legal and technical frameworks with NFT technology. Early-stage research can be financed without endless grant applications, creating a startup and raising VC or needing to file a patent.

Throughout the past 2 weeks VitaDAO Token Holders got to vote on the proposal “VDP-5 Scheibye-Knudsen Lab Funding” to fund longevity at the Scheibye-Knudsen Lab in Copenhagen. The voting passed with 2.1M token votes and 88% of votes supporting the proposition. With the proposal having been approved by the DAO members, the lab in Copenhagen will receive $250.000 for the first research phase of the project over a period of 12 months. After successful completion and review of Phase 1 by the DAO, another $250.000 for an additional 12 months of research could be handed out to the lab. As part of this deal, VitaDAO will fully own the intellectual property (IP) resulting from the research project. The first biopharma IP that will be owned and managed by a DAO. Ownership and access management to the IP will be handled via Molecule’s novel IPNFT framework. The infrastructure is utilizing Ethereum ERC721, Arweave and Nevermined.

Imagine a world where patients directly fund researchers developing the next therapeutic breakthrough they need. One where drug development is collaborative, open, and decentralized — an open bazaar anyone with the right intentions can join. A system that could radically increase the diversity of treatments, and lower costs and time to market.

The pharmaceutical industry is facing a wide variety of challenges, but perhaps the most pressing is the ongoing innovation crisis. Drug discovery rates are declining, the price of bringing a drug to market is increasing, and ROI on R&D is expected to hit 0% in the next few years. Taken together, these factors have a direct impact on the number and types of therapeutics being brought to market. In light of the capital requirements being so high, drug discovery represents a special challenge for its actors, especially pharmaceutical and biotech companies and universities. Compounding these problems, industry and academia struggle with an unprecedented reproducibility crisis. Today, two innovative companies have joined forces to fight these trends.

We decided to create an integration between the Ocean Protocol and Molecule Catalyst, to enable DAO like management of research data produced from the projects funded via Molecule Catalyst, as well as monetize the research data to improve the value of the Molecule Catalyst markets for contributors.